Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ENTA NASDAQ:GLUE NYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$26.71-1.9%$29.83$22.24▼$46.00$1.59B0.581.03 million shs224,330 shsENTAEnanta Pharmaceuticals$14.82+2.3%$13.57$4.96▼$17.15$429.64M1.01180,338 shs83,417 shsGLUEMonte Rosa Therapeutics$20.29+4.8%$17.66$3.51▼$25.77$1.72B1.621.42 million shs413,651 shsNUVBNuvation Bio$4.94+2.4%$4.70$1.57▼$9.75$1.72B1.514.92 million shs3.37 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-3.37%+9.72%-22.70%-1.77%-9.21%ENTAEnanta Pharmaceuticals+0.91%+5.62%+10.20%+7.42%+166.18%GLUEMonte Rosa Therapeutics+2.93%+1.79%+13.22%-0.92%+317.93%NUVBNuvation Bio+8.00%+5.87%+8.73%-17.38%+102.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$26.71-1.9%$29.83$22.24▼$46.00$1.59B0.581.03 million shs224,330 shsENTAEnanta Pharmaceuticals$14.82+2.3%$13.57$4.96▼$17.15$429.64M1.01180,338 shs83,417 shsGLUEMonte Rosa Therapeutics$20.29+4.8%$17.66$3.51▼$25.77$1.72B1.621.42 million shs413,651 shsNUVBNuvation Bio$4.94+2.4%$4.70$1.57▼$9.75$1.72B1.514.92 million shs3.37 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-3.37%+9.72%-22.70%-1.77%-9.21%ENTAEnanta Pharmaceuticals+0.91%+5.62%+10.20%+7.42%+166.18%GLUEMonte Rosa Therapeutics+2.93%+1.79%+13.22%-0.92%+317.93%NUVBNuvation Bio+8.00%+5.87%+8.73%-17.38%+102.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.5655.61% UpsideENTAEnanta Pharmaceuticals 2.75Moderate Buy$20.2936.89% UpsideGLUEMonte Rosa Therapeutics 2.63Moderate Buy$32.8061.69% UpsideNUVBNuvation Bio 2.70Moderate Buy$12.50152.83% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, NUVB, GLUE, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.005/5/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.005/5/2026NUVBNuvation Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.004/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/21/2026NUVBNuvation Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AGIOAgios Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $41.004/20/2026ENTAEnanta Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AGIOAgios Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $50.004/16/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.004/6/2026AGIOAgios Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $36.004/2/2026NUVBNuvation Bio WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M29.39N/AN/A$18.65 per share1.43ENTAEnanta Pharmaceuticals$65.32M6.58N/AN/A$3.03 per share4.89GLUEMonte Rosa Therapeutics$123.67M13.84N/AN/A$3.58 per share5.67NUVBNuvation Bio$62.90M27.32N/AN/A$0.88 per share5.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%N/AENTAEnanta Pharmaceuticals-$81.89M-$3.20N/AN/AN/A-106.80%-78.58%-23.18%5/11/2026 (Estimated)GLUEMonte Rosa Therapeutics-$38.63M-$0.46N/AN/AN/A-31.23%-15.12%-9.30%5/7/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-43.60%-23.76%N/ALatest ENTA, NUVB, GLUE, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q2 2026ENTAEnanta Pharmaceuticals-$0.46N/AN/AN/A$17.03 millionN/A5/7/2026Q1 2026GLUEMonte Rosa Therapeutics-$0.3796N/AN/AN/A$11.41 millionN/A5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 million4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/17/2026Q4 2025GLUEMonte Rosa Therapeutics-$0.45-$0.55-$0.10-$0.55$17.09 million$2.78 million3/2/2026Q4 2025NUVBNuvation Bio-$0.11-$0.11N/A-$0.11$36.82 million$41.87 million2/9/2026Q1 2026ENTAEnanta Pharmaceuticals-$0.54-$0.42+$0.12-$0.42$16.14 million$18.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AGLUEMonte Rosa TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59ENTAEnanta PharmaceuticalsN/A4.444.44GLUEMonte Rosa TherapeuticsN/A6.126.12NUVBNuvation Bio0.156.956.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AENTAEnanta Pharmaceuticals94.99%GLUEMonte Rosa Therapeutics79.96%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%ENTAEnanta Pharmaceuticals11.48%GLUEMonte Rosa Therapeutics6.50%NUVBNuvation Bio30.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableENTAEnanta Pharmaceuticals16029.02 million25.69 millionOptionableGLUEMonte Rosa Therapeutics9084.38 million78.90 millionOptionableNUVBNuvation Bio60347.60 million242.94 millionOptionableENTA, NUVB, GLUE, and AGIO HeadlinesRecent News About These CompaniesNuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer4 hours ago | prnewswire.comNuvation Bio to Participate in Upcoming Investor ConferencesMay 5 at 4:05 PM | prnewswire.comNuvation Bio's (NUVB) "Outperform" Rating Reaffirmed at Royal Bank Of CanadaMay 5 at 12:31 PM | marketbeat.comNuvation Bio (NYSE:NUVB) Earns "Outperform" Rating from WedbushMay 5 at 10:29 AM | marketbeat.comNuvation Bio (NYSE:NUVB) Earns Buy Rating from HC WainwrightMay 5 at 8:32 AM | marketbeat.comNuvation Bio Inc. (NUVB) Q1 2026 Earnings Call TranscriptMay 4 at 10:01 PM | seekingalpha.comNuvation Bio Q1 Earnings Call HighlightsMay 4 at 9:09 PM | marketbeat.comNuvation Bio Inc. (NUVB) Lags Q1 Earnings EstimatesMay 4 at 6:50 PM | zacks.comNuvation Bio (NYSE:NUVB) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPSMay 4 at 4:25 PM | marketbeat.comNuvation Bio Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 4 at 4:10 PM | prnewswire.comNuvation Bio Inc. (NYSE:NUVB) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 3 at 6:51 AM | marketbeat.comNuvation Bio Inc (NUVB) Q1 2026 Earnings Report Preview: What To ExpectMay 1, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)April 30, 2026 | theglobeandmail.comCRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseApril 28, 2026 | zacks.comNuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings GrowthApril 27, 2026 | zacks.comNuvation Bio (NUVB) Projected to Post Earnings on MondayApril 27, 2026 | marketbeat.comNuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System CancersApril 27, 2026 | prnewswire.comA Look At Nuvation Bio’s Valuation After Recent Share Price SwingsApril 23, 2026 | finance.yahoo.com5 Best Small-Cap Biotech Stocks to Buy According to Hedge FundsApril 22, 2026 | insidermonkey.comNuvation Bio Inc (NUVB): Take a Look at Glioma Revenue PotentialApril 22, 2026 | insidermonkey.comAre options traders betting on a big move in Nuvation Bio stock?April 22, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026The Market Is Selling Everything, but These 5 Stocks Aren't Breaking DownBy Bridget Bennett | April 10, 2026JBHT Burns Rubber, Hits the Highway to a $300 Price TagBy Thomas Hughes | April 17, 2026Microsoft Targets Trimmed: What It Means for InvestorsBy Chris Markoch | April 20, 2026Avis, CarMax, and Carvana: 3 Car Stocks Sharply DivergeBy Leo Miller | April 20, 2026ENTA, NUVB, GLUE, and AGIO Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$26.70 -0.51 (-1.86%) As of 12:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$14.82 +0.34 (+2.34%) As of 12:45 PM Eastern This is a fair market value price provided by Massive. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Monte Rosa Therapeutics NASDAQ:GLUE$20.29 +0.94 (+4.84%) As of 12:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Nuvation Bio NYSE:NUVB$4.94 +0.11 (+2.36%) As of 12:46 PM Eastern This is a fair market value price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
